Neutralizing monoclonal antibodies in COVID-19: a case series in general medicine

This article was originally published here

Dtsch Med Wochenschr. 2022 Apr;147(9):558-563. doi: 10.1055/a-1799-1594. Published online April 25, 2022.


BACKGROUND: Neutralizing monoclonal antibodies (mAB) against SARS-CoV-2 reduce the severity of COVID-19 in patients with risk factors. Early administration at the onset of infection is essential for their efficacy. At this early stage of the disease, family physicians are often the first aid for patients and therefore at the heart of the later course of the disease. To date, however, mABs have only rarely been used in general practice. The purpose of this case series is to demonstrate that the administration of mAB is safely feasible in the primary care setting.

CASE REPORT: We report seven cases at risk of severe COVID-19. Two of them were unvaccinated, five had drug immunosuppression and one patient was at high risk due to trisomy-21. All patients were successfully treated with mAB Sotrovimab in a GP practice in January/February 2022. Two patients were treated during a home visit. Based on the cases, clinical information and practical handling of this therapy are described.

CONCLUSIONS: mAB neutralization can be administered safely and with manageable effort in the primary care setting and may help prevent severe course and hospitalization in patients with COVID-19 and risk factors.

PMID:35468637 | DO I:10.1055/a-1799-1594

Comments are closed.